Vor Biopharma Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
VOR$19.56-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity (Deficit)
VOR BIOPH ARMA INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
| CommonStock · AdditionalPaid-In · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit) | |||||||
| Balance, December 31, 2023 | 3,395,072 | $7 | $490,874 | $(77) | $(340,080) | $150,724 | |
| Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes, exercise of stock options, and issuance of common stock under ESPP | 37,711 | — | (56) | — | — | (56) | |
| Issuance of common stock from at-the-market sales agreement | 12,454 | — | 302 | — | — | 302 | |
| Stock-based compensation expense | — | — | 9,847 | — | — | 9,847 | |
| Issuance of common stock from private placement, net of issuance costs | 2,793,562 | 6 | 52,656 | 52,662 | |||
| Other comprehensive income, net of tax | — | — | — | 99 | — | 99 | |
| Net loss | — | — | — | — | (116,914) | (116,914) | |
| Balance, December 31, 2024 | 6,238,799 | $13 | $553,623 | $22 | $(456,994) | $96,664 | |
| Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes, exercise of stock options, and issuance of common stock under ESPP | 115,297 | — | 1,926 | — | — | 1,926 | |
| Issuance of common stock from at-the-market sales agreement | 1,910,861 | 1 | 70,105 | — | — | 70,106 | |
| Stock-based compensation expense | — | — | 18,912 | — | — | 18,912 | |
| Issuance of common stock from private placement, net of issuance costs | 13,876,032 | 2 | 149,883 | — | — | 149,885 | |
| Issuance of common stock from exercise of pre-funded warrants | 5,079,207 | 1 | 86,190 | — | — | 86,191 | |
| Issuance of common stock from underwritten offering, net of issuance costs | 11,500,000 | 1 | 107,965 | — | — | 107,966 | |
| Other comprehensive income, net of tax | — | — | — | 19 | — | 19 | |
| Net loss | — | — | — | — | (695,981) | (695,981) | |
| Balance, December 31, 2025 | 38,720,196 | 18 | 988,604 | 41 | (1,152,975) | (164,312) | |
Vor Biopharma Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.